Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The eBook series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology.
The fourth volume of the series covers the following topics:
- Aspirin administration
- Adenosine receptor targeting for cardiovascular therapy
- Drug treatment of patients with coronary stenting
- Immunosuppressive drugs in heart transplantation
- PCSK9 inhibition for lowering LDL-C levels.
Chapter 1 Should The Argument About Aspirin Dosing Be About Frequency Rather The Dose?
Chapter 2 Adenosine Receptors And Drug Discovery In The Cardiovascular System
Chapter 3 Platelet Reactivity In Patients With Coronary Stenting Treated With Dual Antiplatelet Therapy And After Withdrawal Of Clopidogrel: Impact Of Bioactive Titanium Stent Versus Everolimuscoated Stent
Chapter 4 Immunosuppressive Drugs In Heart Transplantation
Chapter 5 PCSK9 Inhibition With Evolocumab Reaching Physiologic LDL-C Levels For Reducing Atherosclerotic Burden And Cardiovascular Disease- The Full Landscape